4//SEC Filing
O'Loughlin Steve 4
Accession 0001213900-21-046684
CIK 0001388320other
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 5:02 PM ET
Size
5.6 KB
Accession
0001213900-21-046684
Insider Transaction Report
Form 4
O'Loughlin Steve
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-09-01+107,463→ 107,463 totalExercise: $6.07Exp: 2031-09-01→ Common Stock (107,463 underlying)
Footnotes (2)
- [F1]This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.
- [F2]Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.
Documents
Issuer
Actinium Pharmaceuticals, Inc.
CIK 0001388320
Entity typeother
Related Parties
1- filerCIK 0001615840
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 5:02 PM ET
- Size
- 5.6 KB